(12) United States Patent (10) Patent No.: US 8,846,029 B2 Israelsen (45) Date of Patent: Sep
Total Page:16
File Type:pdf, Size:1020Kb
USOO8846O29B2 (12) United States Patent (10) Patent No.: US 8,846,029 B2 Israelsen (45) Date of Patent: Sep. 30, 2014 (54) TREATMENT OF IBD AND IBS USING BOTH 5,591,428 A 1/1997 Bengmarket al. PROBOTC BACTERIA AND FERMENTED &SR 1339. th st al CEREAL ASTREATMENT EFFECTORS 7,220,409- - B2 5/2007 NormanOSSO et ca.al. 7,311.932 B1 12/2007 Berggren et al. (75) Inventor: Hans Israelsen, Allerod (DK) 2004/0028667 A1 2/2004 Norman et al. 2004/0048356 A1 3/2004 Johansson et al. ......... 435/252.3 (73) Assignee: Nordisk Rebalance A/S, Allerod (DK) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 RE 8:15 A. ck 58: U.S.C. 154(b) by 0 days. DE 10258129 A1 6, 2004 EP O 1995.35 A2 10, 1986 (21) Appl. No.: 13/540,827 EP O 1995.35 A3 10, 1986 EP O271364 A2 6, 1988 (22) Filed: Jul. 3, 2012 EP O271364 A3 6, 1988 EP 415941 A1 3, 1991 O O EP O 1995.35 B1 1, 1992 (65) Prior Publication Data EP O271364 B1 9, 1992 US 2012/O269791 A1 Oct. 25, 2012 EP 554418 A1 8/1993 EP O 1995.35 B2 11/1995 WO WO89,05849 A1 6, 1989 Related U.S. Application Data WO WO89,08405 A1 9, 1989 WO WO91/O585.0 A1 5, 1991 (62) Division of application No. 12/066,246, filed as W W. E. A. E. pation No. PCT/DK2006/000526 on Sep. 27, WO WO930.1823 A1 2/1993 WO WO9629O83 A1 9, 1996 WO WO991.8188 A1 4f1999 (60) s sal prov1s1onalapplits applicationCE. No. s 4Y. V: WO WOOWOOO70972 1/70246 A1 11/20009, 2001 filed on Sep. 28, 2005. WO WOO218442 A1 3f2002 WO WOO2,39834 A1 5/2002 (30) Foreign Application Priority Data WO WOO2/O86136 A1 10, 2002 WO WO2004O67731 A1 8, 2004 Sep. 28, 2005 (EP) ..................................... 0.5388070 WO WO2004087893 Al 10/2004 Apr. 12, 2006 (DK) ................................. 2006 OO529 OTHER PUBLICATIONS (51) Int. Cl. AOIN 63/00 (2006.01) Jonkers, D and Stockbrugger, R“Probiotics and Inflammatory Bowel CI2N L/20 (2006.01) Disease” J R Soc Med. Apr. 2003: 96(4): 167-171.* A6 IK35/74 (2006.01) DSMZ “Lactobacillus plantarum” DSMZ catalogue, accessed A 6LX36/899 (2006.01) online (URL:http://www.dsmz.de/catalogues/catalogue-microor A2.3L I/30 (2006.01) ganisms.html#searchResult, retrieved Aug. 27, 2012, 2 pages. A6 IK 45/06 (2006.01) (Continued) A6 IK3I/685 (2006.01) A6 IK35/66 (2006.01) A2.3L. I./72 (2006.01) Primary Examiner—Jon PWeber (52) U.S.AV e. Clwe AssistantSSiStant ExamiExaminer — Aaron JKOSa CPC ......... A61K 35/66 (2013.01); A23 V 2200/3204 (74) Attorney, Agent, or Firm — McLane, Graf, Raulerson & (2013.01); A61 K35/744 (2013.01); A61 K Middleton, PA 36/899 (2013.01); A61 K35/745 (2013.01); s A61K 35/74 (2013.01); A23L I/3014 (2013.01); A23 V 2002/00 (2013.01); A61K 45/06 (57) ABSTRACT (2013.01); A61 K3I/685 (2013.01); A61 K 35/742 (2013.01); A61 K35/747 (2013.01); The invention covers a novel treatment strategy that consid A2.3L I/I 72 (2013.01) erably improves conventional probiotic treatments of inflam USPC ..................................... 424/93.45; 435/252.9 matory bowel diseases, irritable bowel syndrome and other (58) Field of Classification Search gastrointestinal disorders. Both probiotic microorganisms None and the carrier of the probiotic microorganisms in form of a See application file for complete search history. fermented cereal gruel are used as treatment effectors. Phos pholipids may also be an effector. The novel treatment strat (56) References Cited egy is capable of removing the symptoms of inflammatory U.S. PATENT DOCUMENTS bowel diseases regardless of a mild, moderate or severe stage of the disease. 5, 190,755 A 3, 1993 Molin et al. 5,474,932 A 12/1995 Bengmarket al. 5,587,314 A 12/1996 Bengmarket al. 28 Claims, No Drawings US 8,846,029 B2 Page 2 (56) References Cited Stremmel, W. et al., “Delayed Release Phosphatidylcholine as New Therapeutic Drug for Ulcerative Colitis—a Review of Three Clinical OTHER PUBLICATIONS Trials”. Expert Opin. Investig. Drugs, 19(12), pp. 1623-1630, 2010. Stremmel, W. et al., “Retarded Release Phosphatidylcholine Benefits Blandino, A.; Al-Aseeri, M. E.; Pandiella, SS; Cantero, D.; Webb, C Patients with Chronic Active Ulcerative Colitis'. Gut Online, 54:966 "Cereal-based Fermented Foods and Beverages' Food Research 971, 2005. International, 2003, 36(6).pp. 527-543.* Harlow, Brittany E., "Changes to the Equine Hindgut Microflora in Rutgeerts et al., “Optimizing Anti-TNF Treatment in Inflammatory Response to Antibiotic Challenge'. Thesis and Dissertations—Ani Bowel Disease.” Gastroenterology, 2004; 126:1593-1610. mal and Food Sciences, University of Kentucky, Chap. 5, pp. 115 Costello et al., “Dissection of the Inflammatory Bowel Disease 126, 2012. uknowledge.uky.edu/animalsci etds, 12. Transcriptome Using Genome-Wide cDNA Microarrays.” PLoS Mao et al., “The Effects of Lactobacillus Strains and Oat Fiber on Medicine, 2005; 2(8): e199. Methotrexate-Induced Enterocolitis in Rats'. Gastroenterology, Stremmel et al., “Retarded release phosphatidylcholine benefits 1996; 111(2): 334-344. patients with chronic active ulcerative colitis.” Gut, 2005; 54: 966 971. Meroth et al., “Characterisation of the Microbiotica of Rice Sour Bengmark. Stig "Immunonutrition: Role of BioSurfactants, Fiber, doughs and Description of Lactobacillus spicheri sp. nov.”. System and Probiotic Bacteria” Nutrition 1998, 14(7/8), pp. 585-594. atic and Applied Microbiology, 2004; 27: 151-159. Stremmel, U Merle, A Zahn, et al. “Retarded Release Molin, “Probiotics in foods not containing milk or milk constituents, Phosphatidylcholine Benefits Patients with Chronic Active Ulcer with special reference to Lactobacillus plantarum 299 v1-3”, Am. J. ative Colitis” Gut, Jul. 2005,54(7), pp. 966-971. Clin. Nutr. 2001; 73(2s): 380S-385S. Kennedy, R.J., etal “Probiotic Therapy Fails to Improve Gut Perme Niedzielin et al., “A controlled, double-blind, randomized study on ability in a Hapten Model of Colitis' Scand J. Gastroenterol, Dec. 1, the efficacy of Lacotbacillus plantarum 299V in patients with irri 2000, 12, pp. 1266-1271. table bowel syndrome'. Eur, J. Gastroenterol Hepatol., 2001; 13: International Search Report, dated Jan. 15, 2007, which issued during 1143-1147. the prosecution of International Application No. PCT/DK2006/ Nobaek et al., “Alteration of Intestinal Microflora Is Associated With 000526 and a European Search Report dated Dec. 21, 2005, which Reduction in Abdominal Bloating and Pain in Patiens With Irritable issued during the prosecution of EP0538 8079, 5 pages. Bowel Syndrome'. American Journal of Gastroenterology, 2000; Bengmark, “Synbiotic Control of Inflammation and Infection in 95(5): 1231-1238. Transplantation'. Transplantation Reviews, 2004; 18(1): 38-53. Prantera et al., "Inefectiveness of probiotics in preventing recurrence Bengmark and Martindale, "Prebiotics and Synbiotics in Clinical after curative resection for Crohn's disease: a randomised controlled Medicine', Nutrition in Clinical Practice, 2005; 20: 244-261. trial with Lactobacillus GG”, (2002):51: 405-409. Bibiloni et al..."VSL #3 Probiotic-Mixture Induces Remission in Schultzetal."Rationale for Probiotic and Antibiotic Treatment Strat Patients with Active Ulcerative Colitis' American Journal of Gastro egies in Inflammatory Bowel Diseases”. Digestive Diseases, 2003; enterology, 2005: 100: 1539-1546. 21: 105-128. Backhed et al., “Host-Bacterial Mutualism in the Human Intestine'. Science, 2005; 307: 1915-1920. Sen et al., “Effect of Lactobacillus plantarum 299 v on Colonic Fer Christensen et al., “Lactobacilli Differentially Modulate Expression mentation and Symptoms of Irritable Bowel Syndrome', Digestive of Cytokines and Maturation Surface Markers in Murine Dendritic Diseases and Sciences, 2002; 47(11): 2615-2620. Cells. J Immunol, 2002; 168: 171-178. Kato et al., “Randomized placebo-controlled trial assessing the effect Goossens et al., “Survival of the probiotic, L. plantarum 299 v and its of bifidobacteria-fermented milk on active ulceratice collitis' Ali effects on the faecal bacteria flora, with and without gastric acid ment Pharmacol Ther. 2004; 20: 1133-1141. inhibition”. Digestive and Liver Disease, 2005; 37(1): 44-50. Ahrne et al. "Plasmids in Lactobacillus Strains Isolated from Meat Guslandiet al., “A pilot trial of Saccharomyces boulardii in ucerative and Meat Products.” System. Appl. Microbiol. vol. 11, pp. 320-323, colitis' Eur, J. Gastroenterol Hepatol., 2003; 15(6): 697-608. (1989). Ishikawa et al., “Randomized Controlled Trial of the Effect of Cunningham-Rundles et al. “Probiotics and Immune Response.” The Bifidobacteria-Fermented Milk on Ulcerative Colitis’ Journal of the American Journal of Gastroenterology, vol. 95, No. 1, pp. S22-S25. American College of Nutrition, 2002; 22(1): 56-63. (2000). Johansson et al., “Administration of Different Lactobacillus Strains Lidbecket al. “Impact of Lactobacillus acidophilus Supplements on in Fermented Oatmeal Soup: In Vivo Colonization of Human Intes the Human Oropharyngeal and Intestinal Microflora.” Scand. J. tinal Mucosa and Effect on the Indigenous Flora'. Applied and Infect. Dis vol. 19, No. 5, pp. 531-537, (1987). Enviromental Microbiology, 1993; 59(1): 15-20. Osman et al., “Modulation of the Effect of Dextran Sulfate Sodium Kim et al., “A randomized controlled trial of a probiotic VSL#3, on Induced Acute Colitis by the Administration of Different Probiotic gut transit and symptoms in diarrhoea-predominat irritable bowel Strains of Lactobacillus and Bifidobacterium.” Digestive Diseases syndrome”, Aliment Pharmacol Ther. 2003; 17: 895-904. and Sciences, vol. 49, No. 2, pp. 320-327 (2004). Kruis et al., “Mantaining remission of ulcerative colitis with the Stahl et al. "Restriction Endonuclease Patterns and Multivariate probiotic Escherichia coli Nissle 1917 is as effective as with standard Analysis as a Classification Tool for Lactobacillus spp.” Interna mesalazine', Gut, 2004; 53: 1617-1623.